Blog Posts

Bob Li Visited Jules Bordet Institute and Discussed Clinical Trial Access with Oncology Leaders

Bob Li/LinkedIn

Jun 12, 2025, 11:19

Bob Li Visited Jules Bordet Institute and Discussed Clinical Trial Access with Oncology Leaders

Bob Li, SVP Global Head of Medical Affairs, Oncology at AstraZeneca, shared a post on LinkedIn:

“Back in Europe this week for a MARS field visit to the Jules Bordet Institute in Brussels, an internationally-acclaimed cancer center that has pioneered molecular oncology and targeted cancer therapies.

It was great for our cross-functional team to catch up with the President of the Belgian Society of Medical Oncology, Professor Evandro de Azambuja and Dr Elisa Agostinetto for some truly energizing conversations about reinvigorating clinical trials and innovation across Europe.

We really dug into how innovation and decentralization can help us embed greater health equity into our work, and how partnerships to expand community access to clinical trials are moving forward our vision to transform cancer care. Thanks to our team in Belgium for facilitating such a great conversation MARS style!”

More posts featuring the Jules Bordet Institute on OncoDaily.

AstraZeneca Belgian Society of Medical Oncology Bob Li cancer Elisa Agostinetto Evandro de Azambuja https://oncodaily.com/?search=&search_do_advanced=&s=Jules+Bordet+Institute Institut Jules Bordet Jules Bordet Institute MARS molecular oncology OncoDaily Oncology targeted cancer therapy

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Tyler Seibert: 10-year Results of FLAME Trial is Out Now